Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TERT | O14746 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2267970 | 0.99 | LMNA (0.53) | MAPTLMNAHPGDNPC1RAB9A | |
| SCHEMBL2276421 | 0.91 | MEN1 (0.48) | MAPTLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL2270132 | 0.90 | TERT (0.53) | MAPTLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL2269876 | 0.90 | MAPT (0.43) | MAPTLMNAHPGDNPC1RAB9A | |
| SCHEMBL2270415 | 0.90 | HSD17B10 (0.47) | MAPTLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL2270026 | 0.89 | MEN1 (0.50) | MAPTLMNAHPGDALDH1A1MEN1 | |
| SCHEMBL2270372 | 0.86 | DRD2 (0.49) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL2272387 | 0.86 | MAPT (0.40) | MAPTLMNAHPGDALDH1A1MEN1 | |
| SCHEMBL2272135 | 0.86 | ALDH1A1 (0.55) | MAPTLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL2269316 | 0.85 | KMT2A (0.59) | MAPTLMNAALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530465-B2 | 1, 2-disubstituted amido-anthraquinone derivatives, preparation method and application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2013-09-10 | — | — | US | claimed |
| US-20130059862-A1 | Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof | HUANG HSU-SHAN (TW) | 2013-03-07 | — | — | US | claimed |
| US-8530465-B2 | 1, 2-disubstituted amido-anthraquinone derivatives, preparation method and application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2013-09-10 | — | — | US | disclosed |
| US-8530465-B2 | 1, 2-disubstituted amido-anthraquinone derivatives, preparation method and application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2013-09-10 | — | — | US | disclosed |
| US-20130059862-A1 | Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof | HUANG HSU-SHAN (TW) | 2013-03-07 | — | — | US | disclosed |
| US-20130059862-A1 | Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof | HUANG HSU-SHAN (TW) | 2013-03-07 | — | — | US | disclosed |
| US-8304415-B2 | 1, 2-disubstituted amido-anthraquinone derivatives, preparation method and application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2012-11-06 | — | — | US | disclosed |
| US-8304415-B2 | 1, 2-disubstituted amido-anthraquinone derivatives, preparation method and application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2012-11-06 | — | — | US | disclosed |
| US-20110207739-A1 | Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2011-08-25 | — | — | US | disclosed |
| US-20110207739-A1 | Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207739-A1 | Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof | ANXA1, ANXA5, ANXA2 | MAPT 4724/4885LMNA 923/4885HPGD 140/4885 |
| US-20130059862-A1 | Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof | ANXA5, ANXA1, HCCS | MAPT 4820/4885LMNA 1372/4885HPGD 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.